Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $6.05 2.37% 1.99% 660K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
Published: 2022-12-08 (Crawled : 12:00) - globenewswire.com
PHVS | $21.25 -0.19% -0.9% 34K
|
|
| O: 66.93%
H: 184.96%
C: 173.51%
phvs416 treatment positive study
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
PHIO | News | $0.671 -4.14% -4.17% 92K
|
Health Technology
|
| O: -2.94%
H: 175.0%
C: 167.05%
ph-894 disease positive ph94
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $12.74 7.24% 0.0% 430K
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $22.03 -0.36% -0.14% 45K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.4399 -4.35% -1.75% 90K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive therapeutics results glioblastoma
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138Further Supports TTX-MC138 Application in Brain Cancer
Published: 2023-09-25 (Crawled : 17:00) - biospace.com/
RNAZ | $0.4399 -4.35% -1.75% 90K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive cancer application therapeutics results glioblastoma
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.13 -6.17% -6.57% 390K
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $11.83 0.94% -0.17% 20K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.69 -3.69% -3.68% 330K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
NanoVibronix Cites Positive Results from Independent Testing of UroShield
Published: 2023-08-30 (Crawled : 18:00) - biospace.com/
NAOV 4 | $0.75 -2.6% -5.68% 8.7K
|
Health Technology
|
| O: 44.83%
H: 101.43%
C: 15.71%
positive results uroshield
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Published: 2024-03-06 (Crawled : 13:30) - globenewswire.com
NXL | $1.42 -12.62% -8.33% 77K
|
|
| O: -1.61%
H: 95.85%
C: 52.0%
device positive technology results study
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
RVPH | $3.02 -1.31% -1.32% 73K
|
|
| O: 14.58%
H: 91.92%
C: 75.76%
phase 2 schizophrenia positive results trial trial results
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.47 -6.23% -6.65% 740K
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth
Published: 2021-01-19 (Crawled : 17:00) - biospace.com/
SENS | $0.433 0.7% 0.0% 1.4M
|
Electronic Technology
|
| O: 1.27%
H: 86.25%
C: 78.13%
positive
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
Published: 2022-12-13 (Crawled : 13:00) - ir.opgen.com
OPGN | $0.563 -8.16% -5.51% 170K
|
Commercial Services
|
| O: 96.32%
H: 84.47%
C: -5.87%
trial positive infection
SigmaTron International, Inc. Announces Agreement with Its Secured Lenders and Sale of a Majority Position of Wagz, Inc.
Published: 2023-05-04 (Crawled : 17:00) - globenewswire.com
SGMA | $4.1083 1.97% 1.49% 13K
|
Electronic Technology
|
| O: -1.26%
H: 83.83%
C: 48.94%
agreement
Pareteum to Use Voluntary Chapter 11 Process to Facilitate Efficient Sale Process and Position Business for Long-Term Success; Company to Maintain Operations as Usual
Published: 2022-05-16 (Crawled : 04:00) - prnewswire.com
TEUM | $0.0001
|
Communications
|
| O: -12.7%
H: 81.82%
C: -63.64%
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Published: 2024-03-07 (Crawled : 11:00) - globenewswire.com
IMRN | $2.49 1.22% 4.94% 1.3K
|
Health Technology
|
| O: 104.23%
H: 76.85%
C: 35.01%
travelan positive trials results
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.